8 citations,
February 2020 in “Fertility and Sterility” Operative hysteroscopy is still the main treatment for Asherman syndrome, but more research is needed on post-surgery methods.
11 citations,
September 2012 in “Journal of obstetrics and gynaecology Canada” Testosterone therapy seems safe for short-term use in postmenopausal women with low sexual desire, but more research on long-term effects is needed.
10 citations,
January 2015 in “Przeglad Menopauzalny” Progestogens are essential in menopausal hormone therapy to prevent uterine cancer and must be chosen carefully based on individual needs.
82 citations,
January 2000 in “Hormone Research in Paediatrics” DHEA stimulates skin oil glands and could help postmenopausal women, with potential for acne and excessive hair growth treatments.
April 2014 in “Journal of evolution of medical and dental sciences” Women over forty can maintain skin and hair health with lifestyle and dietary changes.
28 citations,
May 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” Testosterone therapy can improve sexual desire and function in postmenopausal women but should be used cautiously and not based solely on testosterone levels.
21 citations,
November 2014 in “Journal of Endocrinological Investigation” Cross-sex hormone therapy is important for managing gender dysphoria and requires careful monitoring and healthcare provider education.
10 citations,
January 2019 in “Archives of Endocrinology and Metabolism” Testosterone therapy may slightly increase sexual desire in women with HSDD but lacks broad recommendation due to safety concerns and limited approval.
251 citations,
October 2014 in “The Journal of Clinical Endocrinology & Metabolism” The guidelines advise against using testosterone and DHEA in women for most conditions due to safety and effectiveness concerns, but suggest considering testosterone for postmenopausal women with low sexual desire.
855 citations,
June 2009 in “The Journal of Clinical Endocrinology & Metabolism” The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.
6 citations,
April 2019 in “Endocrinology and Metabolism Clinics of North America” Testosterone therapy for transmasculine individuals is generally safe with medical supervision, improves mental health, and has mixed effects on physical health.
14 citations,
January 2012 in “Endocrine development” The conclusion is that a thorough approach is needed to diagnose and manage hyperandrogenism in teenage girls, recognizing its major psychological and health effects.
76 citations,
December 2009 in “Clinics in Dermatology” Hormonal treatments can help with acne but are not the first choice due to side effects and the need for careful patient selection.
282 citations,
October 2006 in “The Journal of Clinical Endocrinology and Metabolism” The Endocrine Society advised against routine testosterone therapy for women, citing a need for more research on long-term safety and a clear definition of androgen deficiency.
August 2010 in “Springer eBooks” Hormonal contraceptives are effective for teens but require careful consideration of side effects and individual health.
November 2020 in “AACE clinical case reports” A woman's severe male hormone excess was caused by a small, hard-to-find ovarian tumor.
10 citations,
January 2004 in “KARGER eBooks” Diagnosing PCOS in teenage girls is tricky and requires careful evaluation and management.
1 citations,
November 2023 in “American journal of clinical pathology” Transgender men on testosterone therapy need ongoing gynecologic care due to potential cancer risks.
20 citations,
June 1985 in “Toxicologic Pathology” Some steroid-induced health issues in rodents improved after stopping treatment, but hair loss and eye problems did not.
61 citations,
January 2017 in “Human Reproduction Open” The review recommends hormone replacement therapy for women with premature ovarian insufficiency to manage symptoms and protect health, with specific approaches for different groups.
7 citations,
January 2019 in “Journal of clinical medicine research” Menopause causes significant changes in the vaginal introitus, but less so in the labia majora, which may lead to symptoms of vaginal atrophy.
Older Julia Creek dunnarts often have reproductive and hormonal health issues.
514 citations,
February 2011 in “International journal of women's health” Different treatments for PCOS focus on the specific symptoms, with weight loss and lifestyle changes being important.
July 2015 in “Cambridge University Press eBooks” The document concludes that careful history and physical exams are crucial for accurately diagnosing polycystic ovary syndrome and distinguishing it from other similar conditions.
9 citations,
January 2015 in “Springer eBooks” The document concludes that managing PCOS involves treating symptoms, regulating periods, and reducing health risks, with specific medications for fertility and metabolic issues.
September 2024 in “International Journal of Molecular Sciences” High doses of testosterone disrupt hormone levels and receptor expression in the uterus, affecting fertility.
100 citations,
July 2004 in “The Journal of Sexual Medicine” Hormones like estrogen, testosterone, progesterone, and prolactin play complex roles in female sexual function, with testosterone potentially improving sexual desire, arousal, and satisfaction. However, more research is needed to establish safe and effective hormone treatments for female sexual dysfunction.
67 citations,
September 2008 in “Dermatologic therapy” Hirsutism is excessive hair growth in women often caused by polycystic ovarian syndrome, and identifying the cause is important for managing associated health risks.
March 2024 in “Veterinary sciences” Geriatric Julia Creek dunnarts often suffer from reproductive and skin diseases, impacting conservation efforts.
90 citations,
December 2007 in “Current Oncology” Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.